| Document |
Document Title |
|
JPH0768208B2 |
|
|
JPH0764808B2 |
The invention relates to 9-halo-15-cycloalkyl prostaglandin derivatives of Formula I (I) wherein R1 is hydrogen or methyl, R2 is fluorine or chlorine, n is 0 or 1, and, if R1 is hydrogen, the salts thereof with physiologically compatible...
|
|
JPH0764805B2 |
Compounds of the formula I wherein R1 is hydrogen or hydroxy and R2 is hydrogen or fluorine are described. The compounds of formula I are useful as agents in the treatment of disease states characterized by metabolic calcium deficiencies...
|
|
JPH0764733B2 |
|
|
JPH0764804B2 |
There are disclosed herein novel derivatives of 26,26,26,27,27,27-hexafluorovitamin D3 providing excellent pharmacological effects, and a process for the preparation thereof. These novel compounds are represented by the general formula w...
|
|
JPH0764807B2 |
|
|
JPH0764806B2 |
The novel compounds of the formula in which R is hydrogen or hydroxyl and A is -C IDENTICAL C-; -C=CH- having the E-configuration or -CH2-CH2-, can be used as agents for the treatment of hyperproliferative skin diseases and as agents for...
|
|
JPH0761995B2 |
|
|
JPH0759494B2 |
Process for the preparation of an isomeric mixture of cis- and trans-1-(2,6,6-trimethylcyclohexyl)-hexan-3-ol according to a three-step pathway starting from trimethylcyclohexanone.
|
|
JPH0755960B2 |
New processes for preparing new steroid derivatives including ergosta-1,5,7,22-tetraen-3 beta -ol, 1 alpha -hydroxy-ergosteryl diacetate, etc. which are useful intermediates in the synthesis of 1 alpha -hydroxy vitamin D2. The processes ...
|
|
JPH0751557B2 |
Process for the preparation of retinal by condensation of a C15 sulphide of formula (I) with a C5 haloacetal of formula (II) followed by the hydrolysis and the desulphurisation of the C20 acetal sulphide of formula (III) via the intermed...
|
|
JPH07126246A |
PURPOSE: To obtain the new intermediate consisting of 23-oxo-9,10- secopregna-5,7,10-triene and capable of effectively producing an activated 1α,25- dihydroxyvitamin D3 derivative useful as an agent for treatment and prophylaxis of bone...
|
|
JPH07112968A |
PURPOSE: To stereospecifically obtain the subject compound for e.g. vitamin D pharmaceuticals by reaction of a halogenated methylene derivative of an optically active 6-(4-substituted indene-1-yl)-2-methyl-3-heptanol with an ene-yne deri...
|
|
JPH0739343B2 |
|
|
JPH0739344B2 |
|
|
JPH0737443B2 |
The invention provides a new vitamin D2 compound, 1 alpha -hydroxy-24-epi-vitamin D2 and certain hydroxy-protected derivatives thereof. The new compound exhibits a distinctive activity pattern comprising high potency in stimulating intes...
|
|
JPH0737391B2 |
Production of 26-homo Vitamin D-3 derivatives and intermediates in the production thereof. These compounds express excellent Vitamin-D like activity and could serve in the treatment of various disease states manifesting calcium and phosp...
|
|
JPH0735366B2 |
|
|
JPH0735365B2 |
Process for the preparation of calciferol derivatives of the formula wherein R is hydrogen and the dotted line in the side chain is an optional additional C-C-bond, or R is methyl and the dotted line in the side chain is an additional C-...
|
|
JPH0735367B2 |
|
|
JPH0782151A |
PURPOSE: To prepare a biologically active vitamin D analog, useful as an antagonist to a progesterone and supposed to be usable for controlling the delivery. CONSTITUTION: This delivery controlling agent contains a vitamin D compound in ...
|
|
JPH0725730B2 |
This invention provides novel side chain homologs of 1 alpha ,25-dihydroxyvitamin D3 which exhibit enhanced and highly selective activity in inducing differentiation of malignant cells. It also provides a general method of synthesis appl...
|
|
JPH0770053A |
PURPOSE: To obtain a novel vitamin D derivative comprising a fluorinated 1α, 25-dihydroxy-hexahydrovitamin D derivative, capable of being obtained from inexpensive raw materials in a large amount, and effective as a therapeutic medicine...
|
|
JPH0717597B2 |
This invention relates to a process for making a compound of formula Iin the form of a stereoisomer or mixture thereof, wherein R is hydrogen, lower alkyl; X is hydrogen, halo, trifluoromethyl, lower alkyl or lower alkoxy, and the wavy l...
|
|
JPH0714912B2 |
|
|
JPH0733719A |
PURPOSE: To provide a novel compound which, when administered to warm- blooded animals, induces a bio-affecting response characteristic of the original acid from which the compound is derived and is less irritating and more excellent in ...
|
|
JPH075542B2 |
The present invention discloses a novel, labelled vitamin D3 derivative in which hydrogen atoms on the skeleton portion, i.e. 6- and 19-positions, are substituted with a deuterium atom or a tritium atom, as well as a novel production pro...
|
|
JPH072711B2 |
|
|
JPH072713A |
PURPOSE: To obtain a new compound for the preparation of 1α,25(R),26- trihydroxy-22-ene-cholecalciferol and 1α,25(S),26-trihydroxy-22-ene-cholecarciferol. CONSTITUTION: A compound represented by formula I (W is H, oxygen protecting gro...
|
|
JPH0699454B2 |
This invention provides novel vitamin D-related compounds characterized by extended unsaturated side chain structures. Such compounds exhibit increased activity in arresting the proliferation and promoting the differentiation of malignan...
|
|
JPH06329622A |
PURPOSE: To provide iodo vitamin D3 compounds exhibiting high calcium transport activity with little or no bone calcium mobilization activity and preferably used in the treatment of osteoporosis such as senile, post menopausal, low osteo...
|
|
JPH0692361B2 |
Prostaglandin intermediates of the formula in which Z represents <2bL>C=O or R<1>, together with the oxygen atom to which it is bonded, represents a hydrolysable ester group, R, together with the oxygen atom to which it is bonded, repres...
|
|
JPH0692362B2 |
11-Haloprostane derivatives of general formula I (I) wherein X is F, Cl or Br, R1 is the residue CH2OH or wherein R2 means a hydrogen atom, an alkyl, cycloalkyl, aryl, phenacyl or heterocyclic residue, A is a -CH2-CH2- or cis-CH=CH-group...
|
|
JPH0692305B2 |
|
|
JPH0688926B2 |
Described is an isomer-directed process for producing asymmetric ketones defined according to the generic structure:wherein one of Z, or Z2 is the moiety:and the other of Z1 or Z. is hydrogen; wherein R11 and R21 represent hydrogen or th...
|
|
JPH0689022B2 |
New 24-homo-vitamin D compounds, methods for preparing the same and novel intermediate compounds. The compounds are characterized by vitamin D-like activity of the order of 1 alpha ,25-dihydroxyvitamin D3, the recognized circulating horm...
|
|
JPH0688966B2 |
|
|
JPH0686381B2 |
The use of dehydrocholecalciferal derivs. of formula (I) to make pharmaceuticals for treating diseases of the sebaceous glands is new. (Where R = H or OH; A = CC, (E)-CH=CH or CH2CH2; R'' = H or, where A = C=C, it can also be deuterium)....
|
|
JPH0686421B2 |
|
|
JPH0684348B2 |
The 26,26,26-trifluoro-1 alpha ,25-dihydroxycholecalciferol, particularly the 26,26,26-trifluoro-1 alpha ,25R-dihydroxycholecalciferol essentially free of the 25S-epimer, and the 26,26,26-trifluoro-1 alpha ,25S-dihydroxycholecalciferol e...
|
|
JPH0681728B2 |
|
|
JPH0678354B2 |
Production of 26-homo Vitamin D-3 derivatives and intermediates in the production thereof. These compounds express excellent Vitamin-D like activity and could serve in the treatment of various disease states manifesting calcium and phosp...
|
|
JPH06508121A |
Compounds derived from vitamin D or one of its analogs having, in particular, a lateral chain grafted in position 17 on the D ring of vitamin D. Said compounds are characterized in that they include an epoxide group grafted on said later...
|
|
JPH06256301A |
PURPOSE: To efficiently prepare the compound with a simple process, which is useful as an effective remedy for disorders related to calcium metabolism and skin disorders. CONSTITUTION: The objective 1α,24(R)-dihydroxy- and 1α,24(S)-dih...
|
|
JPH06247926A |
PURPOSE: To obtain an isotopic hydrogen-labeled 1α-hydroxyvitamin D compound of high radioactivity obtainable in high yield without the need for separatory operation of stereoisomers. CONSTITUTION: The isotopic hydrogen-labeled 1α-hydr...
|
|
JPH0667897B2 |
Vitamin D2 and Vitamin D3 derivs of formula (I) (where R is H or Me; R3 is H or a hydroxyl-protecting gp; X and Y are H, 0H or a derivatised 0H; broken line is a single bond or (if R=H) a double bond); are produced from the 7,8-dihydroxy...
|
|
JPH0667899B2 |
This invention provides a novel class of vitamin D-related compounds, namely the 1 alpha -hydroxy-19-nor-vitamin D analogs, as well as a general method for their chemical synthesis. The compounds exhibit pronounced activity in arresting ...
|
|
JPH0667898B2 |
|
|
JPH0667896B2 |
Novel compounds represented by formula (II) are disclosed. They can be easily converted into a fragment corresponding to ring A to be used in a process for binding a fragment corresponding to ring A to fragments corresponding to rings C ...
|
|
JPH0667900B2 |
The present invention provides new compounds, 13,14-dihydro-15-keto-PGFs, and vassopressors containing them, which raise blood pressure without substantial ephemeral depression of blood pressure, trachea or enteron contraction effect inh...
|
